6,678 trials
Diabetes Mellitus, Type 2
Primary: Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS) — -9.20; -9.92…
Pancreatic Cancer
Primary: The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection — 7.9; 8.4 units on a scale
Pertussis · Tetanus · Diphtheria
Primary: Geometric Mean Titers (GMTs) of Tetanus, Diphtheria, and Pertussis Antibodies Pre- and Post-Vaccination With ADACEL® or DECAVAC® Vaccine — 0.501; 0.451; 8.43; 7.23 Titers
Erectile Dysfunction
Primary: Time to Discontinuation of Randomized Treatment — NA; 130; 67 days — p=<0.001
Zollinger-Ellison Syndrome · Multiple Endocrine Neoplasia
Primary: Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment. — 72 participants
Allergic Conjunctivitis to Tree Pollen or Grass Pollen
Primary: Eosinophilic Cationic Protein (ECP) Levels
Contraception
Primary: Retention Rate — 55; 75 percentage of randomized subjects — p=0.4003
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline — -0.13; -0.12 percentage of glycosylated haemoglobin
Bullous Pemphigoid
Primary: Median Time From First Dose of Omalizumab Treatment to Cessation of New Blisters. — 6 weeks
Cognition
Primary: Change From Baseline in Cognitive Function Composite Score - Power of Attention — 1413.67; 1423.38; 1401.21; -5.86 msec — p=0.3771
Anesthesia
Primary: Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes) — 0.32; 0.44; 0.23; 0.32 ratio
Obesity · Critical Illness
Primary: Plasma Concentration of Levofloxacin — 76 mg/L*hr
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2.43; 2.73; 3.69; 2.53 ng/mL
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Chronic Prostatitis Symptom Index (CPSI-F) — 29.6; 35.2 Total CPSI-F
Human Papillomavirus Infection
Primary: Antibody Response to HPV Vaccine for HPV 6,11,16,18. — 1086.49; 1054.13; 745.06; 776.84 Milli Merck Units — p=>0.20